Stavem, K., Ghanima, W., Olsen, M
Plasmacytoid dendritic cells produce excessive type I interferons, driving a cascade of immune activation
Metallomics , 2012, 4(8), 739-750
STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity
Oncotarget 7(25):3846738486 Shaaban S et al (2016) Targeting bone marrow to potentiate the anti-tumor effect of tyrosine kinase inhibitor in preclinical rat model of human glioblastoma
The dosage chart presented here provides a framework, but the clinical nuances, specifically the titration pace, the dose ceiling, the choice of synergistic agents, and the biomarker monitoring schedule, should be individualized by a physician familiar with both the patient's metabolic history and the evolving evidence base for mitochondrial peptide therapy